• Ocular Therapeutix recently enrolled the first patient in its SOL-X long-term extension trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, a 36‑month open-label study designed to assess long-term safety, efficacy, and disease-modifying potential following completion of the SOL-1 or SOL-R trials.
• This extension study is intended to test whether earlier and sustained AXPAXLI therapy can reduce fibrosis, macular atrophy, and treatment burden compared with pulsatile anti-VEGF regimens, potentially broadening the therapy’s clinical and commercial reach if outcomes align with the company’s expectations.
• Against this backdrop, we’ll examine how the launch of the SOL-X extension study may refine Ocular Therapeutix’s AXPAXLI-centered investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix today, you essentially have to believe that AXPAXLI can become a differentiated, durable therapy in wet AMD and justify the company’s heavy spending and premium valuation despite ongoing losses. The launch of the SOL-X extension study looks directionally supportive of that thesis but does not change the key near term catalyst, which remains the AXPAXLI NDA outcome, nor the central risk of dependence on a single lead asset.

Among recent updates, the Eyecelerator 2026 presentation stands out as most relevant: Ocular confirmed it is in formal FDA discussions and preparing an NDA for AXPAXLI, with the potential for a single pivotal trial filing and patent coverage to 2044. Taken together with SOL-X, the story now hinges more clearly on how regulators weigh SOL-1 data and whether long term safety and disease modification evidence ultimately reinforce or weaken AXPAXLI’s positioning.

Yet for investors this growing dependence on one asset also means you should be aware that ...

Ocular Therapeutix's narrative projects $287.1 million revenue and $57.0 million earnings by 2029. This requires 76.8% yearly revenue growth and a $322.9 million earnings increase from -$265.9 million today.

Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 176% upside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts were assuming roughly 32.6% annual revenue growth to about US$121.1 million by 2029, yet still saw AXPAXLI’s concentration and trial risks as serious enough to justify a far lower US$18.0 target, reminding you that reasonable people can look at the same SOL-1 data and reach very different conclusions about how much risk you are really taking on.

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth just $18.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.